Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) (Sirius)

10. september 2026 oppdatert av: Windward Bio

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD). Participants will continue their standard background COPD therapy. Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.

Studietype

Intervensjonell

Registrering (Antatt)

105

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Buenos Aires
      • Buenos Aires, Buenos Aires, Argentina, C1023AAB
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1028AAP
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1122AAK
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1425BEN
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C1425FVH
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires, Argentina, C142ABP
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentina, C1414AIF
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Buenos Aires, Buenos Aires F.D., Argentina, C1426ABP
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Mendoza Province
      • Buenos Aires, Mendoza Province, Argentina, M5500AXR
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Mendoza, Mendoza Province, Argentina, M5500CBA
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000KZD
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Rosario, Santa Fe Province, Argentina, S2013OJN
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Santa Fe, Santa Fe Province, Argentina, S3000ASF
        • Rekruttering
        • WB Contracted Clinical Research Site
    • California
      • Los Angeles, California, Forente stater, 93534
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Florida
      • Miami Lakes, Florida, Forente stater, 33014
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Massachusetts
      • North Dartmouth, Massachusetts, Forente stater, 02747
        • Rekruttering
        • WB Contracted Clinical Research Site
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28277
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Oregon
      • Medford, Oregon, Forente stater, 97504
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Pennsylvania
      • DuBois, Pennsylvania, Forente stater, 15801
        • Rekruttering
        • WB Contracted Clinical Research Site
    • Texas
      • McKinney, Texas, Forente stater, 75069
        • Rekruttering
        • WB Contracted Clinical Research Site
      • Waxahachie, Texas, Forente stater, 75165
        • Rekruttering
        • WB Contracted Clinical Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Adults aged 40 to 80 years
  • Post-BD spirometry at screening FEV1/FVC < 0.70 and FEV1 30-80% predicted
  • On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
  • Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
  • Elevated eosinophil count
  • Weight/BMI within allowed range

Exclusion Criteria:

  • Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)
  • Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
  • Clinically significant cardiovascular disease
  • Recent respiratory infection or COPD exacerbation
  • Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period
  • Pregnancy or breastfeeding
  • Smoking or diagnosed substance use disorder
  • Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: WIN378 Dose 1
WIN378 SC injections will be administered
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
Eksperimentell: WIN378 Dose 2
WIN378 SC injections will be administered
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
Eksperimentell: Placebo
Placebo SC injections will be administered
Placebo matching WIN378

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with Adverse Events (AEs)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Number of participants with Serious Adverse Events (SAEs)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in systolic blood pressure (mmHg)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in diastolic blood pressure (mmHg)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in pulse rate (beats/minute)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in respiratory rate (breaths/minute)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in oxygen saturation (%)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in body weight (kg)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in body mass index (kg/m^2)
Tidsramme: Week 0 - Week 36
Week 0 - Week 36
Change from baseline in body temperature (°C)
Tidsramme: Week 0- Week 36
Week 0- Week 36
Change from baseline in clinical chemistry laboratory assessments
Tidsramme: Week 0 - Week 36
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
Week 0 - Week 36
Change from baseline in haematology laboratory parameters
Tidsramme: Week 0 - Week 36
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
Week 0 - Week 36
Change from baseline in coagulation laboratory parameters
Tidsramme: Week 0 - Week 36
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
Week 0 - Week 36
Change from baseline in urinalysis parameters
Tidsramme: Week 0 - Week 36
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
Week 0 - Week 36
Change from baseline in electrocardiogram QT interval
Tidsramme: Week 0 - Week 36
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
Week 0 - Week 36
WIN378 Serum concentration (PK)
Tidsramme: Week 0 to week 36
Week 0 to week 36

Sekundære resultatmål

Resultatmål
Tidsramme
Change from baseline in Blood Eosinophil Count
Tidsramme: Week 0 to Week 24
Week 0 to Week 24
Change in Fractional Exhaled Nitric Oxide (FeNO)
Tidsramme: Week 0 to Week 24
Week 0 to Week 24
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tidsramme: Week 0 to Week 24
Week 0 to Week 24
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
Tidsramme: Week 0 to Week 24
Week 0 to Week 24
Incidence and magnitude of anti-drug antibodies to WIN 378
Tidsramme: Week 0 to Week 36
Week 0 to Week 36

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Omar Khwaja, MD, Windward Bio

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. juni 2026

Primær fullføring (Antatt)

17. desember 2027

Studiet fullført (Antatt)

7. januar 2028

Datoer for studieregistrering

Først innsendt

2. juni 2026

Først innsendt som oppfylte QC-kriteriene

9. juni 2026

Først lagt ut (Faktiske)

12. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

15. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere